483
Celgene CorporationCelgene Corporation – FDA 483, Sep 12, 2012
Record Details
An FDA inspection of Celgene Corporation in Summit, NJ, revealed significant deficiencies in the conduct and oversight of a clinical investigation. Observations included failures to adhere to the investigational plan and protocols, inadequate study monitoring, and insufficient record-keeping for investigational drug disposition. These issues indicate a lack of control over critical aspects of clinical trial management.
View Company Profile
ID · 785beae0-f6ed-4cb5-9285-f64d1ade00b9
Other documents for Celgene Corporation
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.